anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
As the burden of chronic disease and multiple long-term conditions is increasing globally, disproportionally affecting those in low-resourced settings, there is an increasing call to action to scale effective models of care that can assist in mitigating the impact of chronic disease on functioning, activity, societal participation, and health-related quality of life. The aim of this paper is to unpack the contextual factors that have been implicitly and explicitly voiced by researchers reporting on rehabilitation interventions used to manage chronic disease in low-resourced settings. We systematically engaged the literature and applied a reflexive qualitative and systems thinking lens to unpack the contextual factors and their interplay. A total of 40 different contextual factors were derived through an iterative analysis of 144 eligible articles. The identified factors could be packaged into nine system elements or subsystems relevant to the scale-up of rehabilitation for people with chronic disease. The complexity identified encourages a focus on innovative and intersectoral approaches to address the rehabilitation needs in low-resourced settings.
FIELD: medicine, gynecology. SUBSTANCE: method involves administration of hormonal preparations and normalization of immune status. Dalargin is administrated by the following scheme: 0.001 g intramuscularly once per 24 h for 10 days at the II-d phase of menstrual cycle for 3 months, 2 course per year with 6 months interval. Preparation decreases autosensibilization and shows immunostimulating, reparative and antinoceptive effects, prevents immunosuppressive and other by-side effects of hormonal therapy. Dalargin decreases allergological tolerance of many drugs and ensures to avoid polypragmasy. EFFECT: enhanced effectiveness of treatment, decreased relapses and treatment period. 1 cl
The invention discloses a medicine containing amlodipine besylate and lisinopril dehydrate and a preparation method thereof. Per unit of the preparation is composed of, by weight, 2.5-10 parts of amlodipine besylate, 5-20 parts of lisinopril, 50-200 parts of a filler, 2-10 parts of a disintegrating agent and 0.5-2 parts of a lubricant. A preparation method of the medicine comprises the following steps: mixing: mixing the raw materials and auxiliary materials by an equivalent incremental mode; and tabletting: carrying out direct powder compression on the mixture obtained by the mixing. An amlodipine besylate-lisinopril tablet prepared from the above medicine by the above technology has the following advantages: use of auxiliary materials such as an adhesive, etc. is omitted in comparison with the prior art; the formula is simple; and safety is greatly raised; raw materials and auxiliary materials are mixed by the equivalent incremental mode in the preparation technology so as to ensure content uniformity of the medicine; and steps of granulation, drying and size stabilization, etc. are omitted, the technology is easy to operate, production efficiency is high, and the technology is very suitable for industrial production.
FIELD: veterinary. SUBSTANCE: antistress agent consisting of oak extract enriched with ferrous chloride, potassium, sodium and phosphorus is administrated to animals and poultry as 10% or 0.01% aqueous solution at the dose 0.01 g/kg body mass. The gain weight of animals is 19.2% as compared with control. Agent eliminates the conflict state. Agent is used for prophylaxis and stress treatment in animals. EFFECT: increased effectiveness of agent proposed. 1 tbl
There did not appear to be any increase in drug-related neoplasms following daily topical applications of diclofenac sodium gel for 2 years at concentrations up to 0.035% diclofenac sodium and 2.5% hyaluronate sodium in albino mice. (Note: diclofenac sodium gel, 3% contains 3% diclofenac sodium.) 

When administered orally for 2 years, diclofenac showed no evidence of carcinogenic potential in rats given diclofenac sodium at up to 2 mg/kg/day (3 times the estimated systemic human exposure*), or in mice given diclofenac sodium at up to 0.3 mg/kg/day in males and 1 mg/kg/day in females (25% and 83%, respectively, of the estimated systemic human exposure).

A photococarcinogenicity study with up to 0.035% diclofenac in the diclofenac sodium gel, 3% vehicle gel was conducted in hairless mice at topical doses up to 2.8 mg/kg/day. Median tumor onset was earlier in the 0.035% group (diclofenac sodium gel, 3% contains 3% diclofenac sodium).

Diclofenac was not genotoxic in in vitro point mutation assays in mammalian mouse lymphoma cells and Ames microbial test systems, or when tested in mammalian in vivo assays including dominant lethal and male germinal epithelial chromosomal studies in mice, and nucleus anomaly and chromosomal aberration studies in Chinese hamsters. It was also negative in the transformation assay utilizing BALB/3T3 mouse embryo cells.

Fertility studies have not been conducted with diclofenac sodium gel, 3%. Diclofenac sodium showed no evidence of impairment of fertility after oral treatment with 4 mg/kg/day (7 times the estimated systemic human exposure) in male or female rats.

* Based on body surface area and assuming 10% bioavailability following topical application of 2 g diclofenac sodium gel, 3% per day (1 mg/kg diclofenac sodium).
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. 

The safety of darifenacin extended-release tablet was evaluated in controlled clinical trials in a total of 8,830 patients, 6,001 of whom were treated with darifenacin extended-release tablet. Of this total, 1,069 patients participated in three, 12-week, randomized, placebo-controlled, fixed-dose efficacy and safety studies (Studies 1, 2 and 3). Of this total, 337 and 334 patients received darifenacin extended-release tablets 7.5 mg daily and 15 mg daily, respectively. In all long-term trials combined, 1,216 and 672 patients received treatment with darifenacin extended-release tablets for at least 24 and 52 weeks, respectively. 

In Studies 1, 2 and 3 combined, the serious adverse reactions to darifenacin extended-release tablets were urinary retention and constipation. 

In Studies 1, 2 and 3 combined, dry mouth leading to study discontinuation occurred in 0 %, 0.9 %, and 0 % of patients treated with darifenacin extended-release tablets 7.5 mg daily, darifenacin extended-release tablets 15 mg daily and placebo, respectively. Constipation leading to study discontinuation occurred in 0.6 %, 1.2 %, and 0.3 % of patients treated with darifenacin extended-release tablets 7.5 mg daily, darifenacin extended-release tablets 15 mg daily and placebo, respectively. 

Table 1 lists the rates of identified adverse reactions, derived from all reported adverse events in 2 % or more of patients treated with 7.5 mg or 15 mg darifenacin extended-release tablets, and greater than placebo in Studies 1, 2 and 3. In these studies, the most frequently reported adverse reactions were dry mouth and constipation. The majority of the adverse reactions were mild or moderate in severity and most occurred during the first two weeks of treatment.

Other adverse reactions reported by 1% to 2 % of darifenacin extended-release tablets -treated patients include: abnormal vision, accidental injury, back pain, dry skin, flu syndrome, hypertension, vomiting, peripheral edema, weight gain, arthralgia, bronchitis, pharyngitis, rhinitis, sinusitis, rash, pruritus, urinary tract disorder and vaginitis. 

Study 4 was a randomized, 12-week, placebo-controlled, dose-titration regimen study in which darifenacin extended-release tablet was administered in accordance with dosing recommendations [see Dosage and Administration (2)]. All patients initially received placebo or darifenacin extended-release tablets 7.5 mg daily, and after two weeks, patients and physicians were allowed to adjust upward to darifenacin extended-release tablet 15 mg if needed. In this study, the most commonly reported adverse reactions were also constipation and dry mouth. Table 2 lists the identified adverse reactions, derived from all adverse events reported in greater than 3% of patients treated with darifenacin extended-release tablets and greater than placebo.
<P>PROBLEM TO BE SOLVED: To provide a product information management system which is user-friendly making very little load for a product purchaser, and can reduce a commodity risk.  <P>SOLUTION: The product information management system searches a customer information management server 3 which stores a customer information containing a customer's purchase product information, a customer's name, etc. at a customer information management database 3DB, and registers and manages the customer as a member, a product relevant information database 6DB which stores product relevant information including a manual information on the product, risk information to the product, and guarantee information on the product, and the customer information of the customer which is in agreement with customer identification information of this consumer terminal from a customer information management server 3, when an offering request of an online shopping means of the product and the product relevant information of a customer purchase product are received. Meanwhile, the system searches from a manual management server 6 the product relevant information which is in agreement with an attribute information of the purchase product. The system also has a shop server 10 and a consumer terminal 9 displaying these searched product relevant information and the customer information on a member's portfolio.  <P>COPYRIGHT: (C)2011,JPO&INPIT
This condition will be prescribed the Traffic Light Diet (1000-1500 kcal/day, \< 2 servings/day of RED \[non-nutrient-dense, energy-dense\] foods) and a \> 60 min/day of MVPA prescription for children and \> 30 min/day of MVPA for adults at least 5 days/week. FBT will receive a family-based, behavioral intervention to assist the targeted child and a participating adult caregiver with making changes in energy balance behaviors.
A novel patented Prodovite® VMP35 Multi-Nutrient-Complex (MNC), a vitamin, mineral, and phytonutrient encapsulated liquid formulation, was prepared using a novel proprietary SK713 SLP multi-lamellar clustoidal non-GMO phospholipid Prodosome nutrient absorption/delivery technology in a state-of-the-art multistep cGMP and NSF-certified manufacturing facility. This developmental technology is biodegradable and biocompatible. Preliminary study in our laboratory demonstrated the efficacy of Prodovite® VMP35 in Sports Nutrition. We hypothesize that Prodovite® VMP35 supplement will enhance athletic performance, lean-body muscle mass, increase exercise tolerance, and improve anabolic parameters in healthy human subjects. The aim of this pilot study is to evaluate the effect of oral supplementation of Prodovite® VMP35 on exercise endurance, muscle strength, anabolic parameters and lean body mass in healthy human subjects. We hypothesize that Prodovite® VMP35 supplementation will enhance and increase exercise performance, tolerance, lean-body muscle mass, improve anabolic parameters and blood chemistry parameters in healthy human subjects. Accordingly, 150 healthy male and female subjects will be randomly assigned to receive either Prodovite® VMP35 or placebo in the form of single dose sealed containers for 90 consecutive days and muscle strength, endurance, speed, anabolic/catabolic parameters and muscle mass will be evaluated by dual energy X-ray absorptiometry (DEXA), hand-grip strength test, cycle ergometer test, spirometer assessment and assay of Blood chemistry and serum biomarkers will be evaluated before and after intervention.
Described herein is a method of diagnosing Lyme disease in a subject. The method includes determining a glycosylation profile of a protein whose glycosylation profile is associated with Lyme disease in a subject, and comparing the glycosylation profile of the protein with a predetermined glycosylation profile of the protein indicating free of Lyme disease or a predetermined glycosylation profile of the protein indicating Lyme disease. Further described herein is a method of treating and/or ameliorating Lyme disease in a subject. The method includes diagnosing Lyme disease in a subject and, if the subject is diagnosed to have Lyme disease, administering to the subject an effective amount of compound effective for treating Lyme disease. Further described herein is a method of evaluating a treatment for Lyme disease. The method includes comparing a glycosylation profile of the patient with glycosylation profiles associated with successful/unsuccessful treatments.
PCT No. PCT/JP94/02057 Sec. 371 Date Jun. 5, 1996 Sec. 102(e) Date Jun. 5, 1996 PCT Filed Dec. 7, 1994 PCT Pub. No. WO95/15980 PCT Pub. Date Jun. 15, 1995Synthetic peptides containing the following specific sequence: Xaa-Pro-Val-Xbb-Xcc-Lys-Arg-W (wherein Xaa is absent or represents Cys or Ser, Xbb represents His or Asn, Xcc represents Leu or Ile and W represents a hydrophobic peptide portion.), an intermediate for producing the peptide, a process for producing the peptide, a lung surfactant comprising the peptide and a lipid mixture and a remedy for respiratory distress syndrome containing the surfactant as the active ingredient. The peptide is easy to isolate and purify and suitable for mass production. As it is highly soluble in methanol and the like, it can readily be blended with a lipid mixture and is suited for the preparation of a lung surfactant. As the lung surfactant has a good supensibility and a potent surface activity, it is useful as a remedy for respiratory distress syndrome.
The invention relates to a glipizide film-controlled slow-release pellet capsule. A slow-release film of the glipizide film-controlled slow-release pellet utilizes Eurdragit RL 30D as a film-formation material. A pellet core of the glipizide film-controlled slow-release pellet contains sodium carboxymethyl starch having high expansibility, and also contains pharmaceutically-acceptable common excipients for the slow-release pellet, wherein preferably, the excipients comprise microcrystalline cellulose, lactose and sodium dodecyl sulfate, and the pellet core comprises 5 to 20wt% of sodium carboxymethyl starch. The slow-release film comprises Eurdragit RL 30D, triethyl citrate as a plasticizer and talcum powder as an antiplastering aid, wherein preferably, a ratio of Eurdragit RL 30D to triethyl citrate to talcum powder is 30: 3: 4 and a film weight increasing ratio is in a range of 17 to 36%. The glipizide film-controlled slow-release pellet comprises the pellet core containing sodium carboxymethyl starch having high water expansibility and thus after absorbing water, the glipizide film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the glipizide film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.
OBJECTIVES: I. Evaluate the safety and tolerability of subcutaneous trastuzumab (Herceptin) plus paclitaxel in women with HER2 overexpressing metastatic breast cancer. II. Assess the activity of this treatment regimen in these patients. III. Determine the pharmacokinetics of trastuzumab and paclitaxel in this regimen.

OUTLINE: This is a randomized, open label, multicenter study. Patients are randomized to one of two treatment arms. Patients receive a loading dose of trastuzumab (Herceptin) IV over 90 minutes followed by paclitaxel IV over 3 hours on day 0. Paclitaxel is repeated every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Arm I: Patients receive trastuzumab subcutaneously (SC) weekly starting day 7. Arm II: Patients receive trastuzumab SC twice weekly starting day 7. Treatment with trastuzumab SC continues for 48 weeks in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 80 patients (40 per treatment arm) will be accrued for this study.
BACKGROUND: Elevated central venous pressure (CVP) is deemed as a sign of right ventricular (RV) dysfunction. We aimed to characterize the echocardiographic features of RV in septic patients with elevated CVP, and quantify associations between RV function parameters and 30-day mortality.
METHODS: We retrospectively reviewed a cohort of septic patients with CVP ≥ 8 mmHg in a tertiary hospital intensive care unit. General characteristics and echocardiographic parameters including tricuspid annular plane systolic excursion (TAPSE), pulmonary vascular resistance (PVR) as well as prognostic data were collected. Associations between RV function parameters and 30-day mortality were assessed using Cox regression models.
RESULTS: Echocardiography was performed in 244 septic patients with CVP ≥ 8 mmHg. Echocardiographic findings revealed that various types of abnormal RV function can occur individually or collectively. Prevalence of RV systolic dysfunction was 46%, prevalence of RV enlargement was 34%, and prevalence of PVR increase was 14%. In addition, we collected haemodynamic consequences and found that prevalence of systemic venous congestion was 16%, prevalence of RV-pulmonary artery decoupling was 34%, and prevalence of low cardiac index (CI) was 23%. The 30-day mortality of the enrolled population was 24.2%. In a Cox regression analysis, TAPSE (HR:0.542, 95% CI:0.302-0.972, p = 0.040) and PVR (HR:1.384, 95% CI:1.007-1.903, p = 0.045) were independently associated with 30-day mortality.
CONCLUSIONS: Echocardiographic findings demonstrated a high prevalence of RV-related abnormalities (RV enlargement, RV systolic dysfunction and PVR increase) in septic patients with elevated CVP. Among those echocardiographic parameters, TAPSE and PVR were independently associated with 30-day mortality in these patients.
In the international guidelines, higher thrombolysis in myocardial infarction frame count (TFC) is indicated as evidence of coronary microvascular dysfunction (CMD). However, the association of TFC with invasively measured coronary physiologic parameters such as coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) remains unclear. Patients without significant epicardial coronary lesions underwent invasive coronary physiologic assessment using a thermodilution method in the left anterior descending artery. Corrected TFC (cTFC) was evaluated on coronary angiography. The cut-off values of CFR and IMR were defined as ≤2.0 and >25, and patients with abnormal CFR and/or IMR were defined as having CMD. This study aimed to assess whether cTFC >25, a cut-off value in the guidelines, was diagnostic of the presence of CMD. Of the 137 patients, 34 (24.8%) and 32 (23.3%) had cTFC >25 and CMD, respectively. The rate of CMD was not significantly different between patients with and without cTFC >25. cTFC was weakly correlated with at rest and hyperemic mean transit time and IMR, whereas no significant correlation was observed between cTFC and CFR. The receiver operating characteristic curve analysis showed the poor diagnostic ability of cTFC for abnormal CFR and IMR and the presence of CMD. In conclusion, in patients without epicardial coronary lesions, cTFC as a continuous value and with the cut-off value of 25 was not diagnostic of abnormal CFR and IMR and the presence of CMD. Our results did not support the use of cTFC in CMD evaluation.
PURPOSE:To obtain a treated ginseng by disintegrating tissue-cultured ginseng with ultrasonic vibration. CONSTITUTION:Root of ginseng (e.g Panax ginseng, Panax japonicum, etc.) is aseptically cultured to obtain a tissue-culture product, which is treated with ultrasonic vibration (1kHz-1MHz, preferably 10-50kHz) to obtain treated ginseng. The treatment is carried out by dispersing the cultured product in a proper solvent (e.g. water, alcohol such as methanol, ketone such as acetone, polyhydric alcohol such as glycerol, etc.) and irradiating the dispersion with ultrasonic vibration. The treated product contains various active components such as saponins, inorganic salts, flavonoids, etc. The treated product and extract prepared therefrom can be utilized as ginseng preparation or various health foods. Since the active component is released from the cell, it can be quickly absorbed even by taking the disintegrated cell as it is and a sufficiently high drug action can be attained.
Placebo Xiao zhong fang granules were made by the same institution. Placebo granules 6 days for one course, continuously taking two courses, interval of 1 day, and then take 2 courses. Short wave infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
Compounds of general formula (I) in which R1? represents a hydrogen atom or a hydroxyl protecting group, R2? represents a hydrogen atom or a carboxyl protecting group, and R3? represents the group N(R4?)-CH=NR5? wherein R4? represents a hydrogen atom and R5? represents a hydrogen atom; and salts, metabolically labile esters and solvates thereof and a process for their production. The compounds of formula (I) are either antibacterial agents and/or useful intermediates for the preparation of antibacterial agents.
The topical preparation contains 1000mg of cannabinoids per ounce. The other ingredients are the same in both arms.
The invention belongs to the technical field of traditional Chinese medicine, and relates to a traditional Chinese medicine compound Shenfu drop pill, preparation raw materials, a preparation method and application thereof. The drop pill solves the technical problems of inconvenient administration and large dose, etc. Raw materials for preparing the traditional Chinese medicine compound Shenfu drop pill comprise red ginseng, prepared common monkshood daughter root and a substrate; the red ginseng and the prepared common monkshood daughter root are in a weight ratio of 3:4-5:2; effective components of the red ginseng and prepared common monkshood daughter root are extracted to obtain a Shenfu extractive; and a weight ratio of the Shenfu extractive to the substrate is 1:1.5-1:3. The preparation method comprises steps of: A, preparation of the Shenfu extractive; B, melting and mixing; and C, dripping. The drop pill has the advantages of high efficiency, quick acting, long acting, low toxicity, mild reaction, small dosage, and convenience for production, transportation, usage, carrying and preservation. Compared with solid preparation such as a capsule, the drop pill has obvious curative effect, high bioavailability and enhanced stability, so as to truly achieve quickness and effectiveness.
Participants will insert one Dapivirine Vaginal Ring, 25 mg to be replaced every 4 weeks for 8 weeks, then worn for an additional 5 weeks for a total of 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.